AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference

    CASTLE ROCK, Colo., Feb. 14 /PRNewswire-FirstCall/ -- AspenBio Pharma,
 Inc. (Nasdaq:   APPY) an emerging bio-pharmaceutical company dedicated to the
 development of novel drugs and diagnostics for animals and humans, has been
 invited to present at the 20th Annual Roth Capital Partners Growth Stock
 Conference. The conference will be held February 18-21, 2008 at the Ritz
 Carlton Laguna Niguel in Dana Point, California.
 
     Roth Capital Partners Stock Conferences are one of the largest in the
 nation for micro and small-cap companies in technology, healthcare,
 financial services and consumer products sectors. More than 1,000
 institutional investors are expected to attend.
 
     AspenBio's president and CEO, Richard Donnelly, is scheduled to present
 on Tuesday, February 19 at 3:00 PM Pacific Time (6:00 PM Eastern Time),
 followed by a break out session and one-on-one meetings. A simultaneous
 Webcast will be available at http://www.wsw.com/webcast/roth16/appy/.
 
     For more information on the Roth conference, please visit the
 conference website at http://rothconference.com or call the conference desk
 at 800-678-9147. For media inquiries and press credentials only call
 949-720-5700.
 
     About Roth Capital Partners, LLC
 
     With corporate headquarters in Newport Beach, California and offices in
 strategic locations in the Western United States and Shanghai, China, Roth
 Capital Partners, LLC is a full service investment bank serving corporate
 and institutional clients throughout the world. Offering a wide array of
 investment banking services including: initial public offerings,
 follow-ons, PIPEs, private placements, mergers and acquisitions, investment
 research, and institutional sales and trading, the firm is perhaps best
 known for finding, funding and fostering the growth of emerging companies.
 It is a member of the Financial Industry Regulatory Authority, Inc.
 ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit
 the Roth Capital Partners website at http://www.rothcp.com.
 
     About AspenBio Pharma, Inc.
 
     AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to
 the discovery; development, manufacture, and marketing of novel proprietary
 products, including those that enhance the reproductive efficiency of
 animals and that have large worldwide market potential. The company was
 originally formed to produce purified proteins for diagnostic applications
 and has become a leading supplier of human hormones to many of the nation's
 largest medical diagnostic companies and research institutions. The company
 has successfully leveraged this foundational science and technology
 expertise to rapidly develop an enviable late-stage pipeline of several
 novel reproduction hormone analogs for wide-ranging therapeutic use
 initially in bovine and equine species. AspenBio Pharma continues to
 advance the development and testing of its two first-generation blood-based
 human diagnostic tests designed to rapidly help diagnose or rule out
 appendicitis in patients complaining of abdominal pain. For more
 information, go to http://www.aspenbiopharma.com.
 
 

      Investor Relations:
      Liolios Group, Inc.
      Ron Both
      Tel 949-574-3860
      info@liolios.com
 
 

SOURCE AspenBio Pharma, Inc.